Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 6—June 2006

Dispatch

Antiretroviral Drug Resistance and Routine Therapy, Cameroon

Christian Laurent*Comments to Author , Charles Kouanfack†, Laurence Vergne*, Michèle Tardy†, Léopold Zekeng‡§, Nathalie Noumsi†, Christelle Butel*, Anke Bourgeois*, Eitel Mpoudi-Ngolé¶, Sinata Koulla-Shiro†, Martine Peeters*, and Eric Delaporte*
Author affiliations: *Institut de Recherche pour le Développement (UMR 145), Montpellier, France; †Central Hospital, Yaoundé, Cameroon; ‡Laboratoire de Santé et d'Hygiène Mobile, Yaoundé, Cameroon; §National AIDS Program, Yaoundé, Cameroon; ¶Military Hospital, Yaoundé, Cameroon

Main Article

Table

Antiretroviral drug resistance in 21 patients receiving multiple ART in a routine care setting in Cameroon*

Patient no. Age Sex Antiretroviral drugs received Months from start of ART Drug resistance Major genotypic mutations Subtype pol
2-29 46 F 3TC, ZDV, EFV 33 3TC, FTC, EFV, NVP M184V, K103N, P225H CRF02-AG
2-44 49 F 3TC, ZDV, EFV 10 3TC, FTC, EFV, NVP M184V, (K70R), K103N, Y188L CRF02-AG
2-47 42 M 3TC, ZDV, IDV 10 3TC, FTC M184V CRF02-AG
2-59 36 F 3TC, ZDV, EFV, IDV 52 3TC, ZDV, d4T, FTC, EFV, NVP M184V, T215F, (M41L), K103N CRF02-AG
2-66 36 M 3TC, ZDV, d4T, ddI, EFV 21 3TC, FTC, EFV, NVP M184V, K103N CRF02-AG
2-70 30 M d4T, ddI, EFV 6 EFV, NVP K103N CRF02-AG/F
2-75 37 F 3TC, d4T, IDV 9 3TC, FTC M184V A
2-76 34 M 3TC, d4T, EFV 10 3TC, ZDV, d4T, FTC, EFV, NVP M184V, T215Y, K103N F2
2-84 51 M 3TC, ZDV, d4T, ddI, NFV 48 NRTIs, NFV K65R, M184V, Q151M, N88D D
2-91 44 M 3TC, d4T, EFV, IDV 6 EFV, NVP G190E CRF02-AG/F
2-98 32 F d4T, ddI, IDV 7 IDV, RTV V82A D
22-2 42 M 3TC, ZDV, EFV 14 3TC, FTC, EFV, NVP M184I, (M41L), K101E, K103N CRF02-AG
22-9 33 F 3TC, ZDV, d4T, ddI, EFV, IDV 31 3TC, FTC, EFV, NVP M184V, K103N, P225H CRF11-cpx
22-25 30 F 3TC, ZDV, EFV, IDV 18 3TC, FTC M184V CRF02-AG
22-31 42 M 3TC, d4T, IDV 8 3TC, FTC M184V CRF02-AG
22-33 41 F 3TC, ZDV, IDV 18 3TC, FTC M184V CRF02-AG
22-35 58 M 3TC, ZDV, IDV 17 ATV, IDV, RTV V82A CRF01-AE
22-47A 48 F 3TC, ZDV, EFV, IDV 45 3TC, ZDV, d4T, FTC, EFV, NVP M184V, T215F, (D67N, K70R, K219Q), K103N, Y188L CRF02-AG
22-50 32 M 3TC, d4T, NVP 6 3TC, FTC, TDF, (ABC, ddI), EFV, NVP K65R, M184V, Y181C CRF01-AE
22-57 53 M 3TC, ZDV, EFV 7 EFV, NVP K103N CRF02-AG
22I-75 50 F 3TC, ZDV, d4T, ddI, EFV, IDV 29 3TC, ZDV, d4T, FTC, EFV, NVP M184V, T215F, (D67N, K70R, K219E), K103N CRF02-AG

*ART, antiretroviral therapy; 3TC, lamivudine; ZDV, zidovudine; EFV, efavirenz; FTC, emtricitabine; NVP, nevirapine; IDV, indinavir; d4T, stavudine; ddI, didanosine; NFV, nelfinavir; NRTIs, nucleoside reverse transcriptase inhibitors; ATV, atazanavir; RTV, ritonavir; TDF, tenofovir; SQV, saquinavir; ABC, abacavir. Resistances in parentheses indicate possible resistances. Mutations in parentheses indicate thymidine analogue mutations.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO